Three-dimensional structure of a Nanobody® (modeled on the VHH with pdb-code 1U0Q, Cambillau et al). The target molecule is recognized by the surface formed by three hypervariable regions located at the top of the molecule (in green, cyan and blue). Hallmarks, amino acid residues that further differentiate a camelid VHH from a human VH, can be located at different positions within the framework regions, and here are coloured red, pink and magenta.

Home INVESTOR RELATIONS NEWSROOM > PRESS RELEASES

Press Releases

27/07/2010

ABLYNX ANNOUNCES CHANGE IN MANAGEMENT

23/07/2010

ABLYNX ANNOUNCES WARRANT EXERCISE

12/07/2010

NOVARTIS OBTAINS LICENSES TO DEVELOP AND COMMERCIALISE TWO NOVEL NANOBODIES®

05/07/2010

ABLYNX SECURES €1.5 MILLION IN GRANTS

28/06/2010

ABLYNX WINS EUROPEAN MEDISCIENCE AWARD FOR THE SECOND YEAR IN A ROW

22/06/2010

ABLYNX EXPANDS INTO NEW R&D FACILITIES

15/06/2010

ABLYNX ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE 5th ANNUAL PIPER JAFFRAY EUROPE HEALTHCARE CONFERENCE

02/06/2010

ABLYNX AND REMYND SETTLE DISPUTE AMICABLY

24/05/2010

NANOBODY® LEAD CANDIDATE SELECTED BY BOEHRINGER INGELHEIM FOR DEVELOPMENT IN ALZHEIMER'S DISEASE

20/05/2010

ABLYNX ANNOUNCES A THIRD EXTENSION OF ITS ANTI-TNF-ALPHA NANOBODY COLLABORATION WITH PFIZER

19/05/2010

ABLYNX PROVIDES A BUSINESS UPDATE FOR THE FIRST QUARTER 2010

30/04/2010

PUBLICATION IN ACCORDANCE WITH ARTICLE 15 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

23/04/2010

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

13/04/2010

SPO OVER-ALLOTMENT OPTION PARTIALLY EXERCISED

26/03/2010

ABLYNX SELECTS A NOVEL PRE-CLINICAL DEVELOPMENT CANDIDATE FOR ADMINISTRATION VIA PULMONARY DELIVERY

25/03/2010

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

18/03/2010

PUBLICATION IN ACCORDANCE WITH ARTICLE 15 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

15/03/2010

ABLYNX SUCCESSFULLY RAISES €50 MILLION WITH SECONDARY PUBLIC OFFERING - FINAL PRICE: €7.5 PER SHARE

08/03/2010

ABLYNX INTENDS TO RAISE UP TO €57.5 MILLION WITH SECONDARY PUBLIC OFFERING - PRICE RANGE: €7.20 - €7.75 PER SHARE

25/02/2010

ABLYNX PLANS A SECONDARY PUBLIC OFFERING ON EURONEXT BRUSSELS

25/02/2010

ABLYNX ANNOUNCES 2009 FULL YEAR RESULTS

22/02/2010

ABLYNX RESPONDS TO PRESS REPORTS

22/02/2010

ABLYNX WILL ANNOUNCE FULL YEAR RESULTS FOR 2009 WITH WEBCAST

19/02/2010

ABLYNX RECEIVES €1.2 MILLION GRANT TO FURTHER ADVANCE ITS ANTI-IL-6R PROGRAMME, ALX-0061

11/02/2010

ABLYNX WINS PATENT OPPOSITION CASE AGAINST DOMANTIS (GSK)

11/02/2010

ABLYNX SELECTS GPCR TARGETING DEVELOPMENT CANDIDATE, ANNOUNCES NEW DATA ON ALTERNATIVE ROUTES OF DELIVERY FOR NANOBODIES AND PROVIDES AN R&D UPDATE

22/01/2010

ABLYNX ANNOUNCES WARRANT EXERCISE

11/01/2010

ABLYNX SUCCESSFULLY GENERATES NANOBODIES® AGAINST AN ION CHANNEL AND ANNOUNCES NEW GPCR PROGRAMME

06/01/2010

ABLYNX ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE 28TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

 

Press releases

  • 2010

News archive

Email alerts

If you would like to receive updates on the company news, please
click here